NEW YORK, NY / ACCESS Newswire / September 17, 2025 / Every once in a while, an industry has its thunderbolt moment.
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...
NEW YORK, NY / ACCESS Newswire / September 17, 2025 / Every great industry eventually faces the same showdown. Not over who builds the best technology or who moves the fastest, but over who writes the ...
Prestigious three-year multicenter clinical trial confirms revolutionary implantable lens technology achieves exceptional visual outcomes with minimal complications Dr. Jason P. Brinton of Brinton ...